Every revenue stream emerges from the same intelligence core. Nothing is bolted on. Everything compounds.
Ten revenue streams distributed across three concentric rings
The foundation. Recurring SaaS revenue from tiered intelligence delivery.
Direct sales from walkthrough → dossier → deployment call pipeline. Upsell from Signal to higher tiers as organizations see compounding value.
Unlike consulting (project-based), intelligence compounds. Cancellation means losing institutional memory.
When the intelligence engine detects a client need that matches a partner specialty, it routes a warm, context-rich introduction.
Insurance specialists, regulatory consultants, BD/licensing advisors, IP attorneys, clinical trial consultants, market access strategists.
Build opt-in partner directory. Engine detects need from client signals. Referral fee on successful engagement (15-25% of first engagement or ongoing rev-share).
Zero incremental CAC. Partners get pre-qualified leads they can't access elsewhere. Clients get vetted experts at the exact moment of need.
Single-seat clients expand to multi-seat, multi-department, and eventually white-label deployments.
Land with one champion (usually BD or strategy lead), expand to executive team, then research, then regulatory. Each department gets role-specific views. Enterprise contracts replace individual subscriptions.
Once institutional memory accumulates, switching costs become enormous. The system knows their competitors, their pipeline, their regulatory timeline.
Anonymized, aggregated intelligence reports sold to the broader industry. Sector-level insights derived from the collective intelligence of all client deployments.
Once sufficient client base exists (50+ organizations), aggregate anonymized signals into quarterly sector reports. Sell to investment banks, consulting firms, government agencies.
Data is already being processed. Aggregation and anonymization create a new product at near-zero marginal cost.
AI literacy and intelligence operations courses for biopharma professionals.
Intelligence-driven decision-making, AI literacy for regulated environments, and AimwellBio platform mastery. Certification becomes industry-recognized.
Positions AimwellBio as the authority on biopharma intelligence. Trained users become advocates and buyers.
National health agencies, government pharmaceutical organizations, and sovereign wealth-backed health initiatives.
Purpose-built deployments with data sovereignty (in-country hosting), custom compliance frameworks, and dedicated support. Entry through existing enterprise relationships or direct government procurement.
Governments spend billions on health intelligence with fragmented, outdated tools. A verified, sovereign-deployable intelligence system fills an enormous gap.
Expert network directory where partners are surfaced contextually to clients who need them.
Partners opt in and set availability. Engine matches client needs to partner expertise. Platform facilitates introduction. Revenue share on successful engagements.
Marketplace effect — more partners attract more clients, more clients attract more partners. AimwellBio captures margin on every transaction.
The adversarial intelligence engine deployed as a standalone API. Any biotech organization can run 4-agent adversarial validation on any strategic decision — without a full AimwellBio subscription.
Four specialized agents — Regulatory, Competitive, Trial Failure, Capital Risk — run in parallel. Consensus scoring returns PROCEED / DELAY / KILL with full justification chains. Every run seeds institutional memory.
Per-validation pricing ($49–$299/run based on depth). Enterprise volume packages. White-label API for consulting firms and CROs to embed in their own workflows.
Zero integration friction — single API call returns structured JSON. Creates a top-of-funnel that converts pay-per-use customers to full subscriptions.
The FHIN contributor network generates a continuously-updated corpus of expert-curated biomedical signals, failure patterns, and regulatory intelligence — licensable to institutions that can't access it otherwise.
Anonymized failure pattern database indexed by therapeutic area, phase, and failure mode. Regulatory signal corpus with contributor confidence scores. Clinical trial outcome predictions from verified expert consensus.
Annual data licensing to academic institutions, CROs, investment funds, and pharma analytics teams. Tiered by data volume, refresh frequency, and domain specificity. Minimum $50K/yr.
The data doesn't exist anywhere else. FHIN contributors are verified domain experts. Failure patterns are validated against real outcomes — not synthetic or scraped.
Programmatic access to the AimwellBio intelligence stack. External developers, analytics platforms, and enterprise systems connect directly to signals, cortex memory, and adversarial validation.
/cortex-search semantic search across institutional memory. /run-adversarial-validation 4-agent engine. /ingest-fhin-signal expert signal submission. /get-contributor verified contributor profiles. Webhook events for sub-hour signal delivery.
API key tiers — Starter ($99/mo, 1K calls), Professional ($299/mo, 10K calls), Enterprise (custom). Python and TypeScript SDK packages. Partner integrations with EMR systems, CRMs, and analytics platforms.
Every API integration creates a dependency layer. Once an enterprise analytics platform is piping AimwellBio signals into their workflows, switching cost is enormous.
Conservative scaling model with early focus on subscription foundation
Every client deployment makes the engine smarter. Every partner integration creates a new revenue surface. Every data point processed increases the switching cost for every organization that depends on it. This is not a product roadmap. This is a compounding machine.